| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Roya Khosravi-Far | |
| Jessica Plati | |||
| Octavian Bucur | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib | Q21563446 | ||
| Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner | Q22008727 | ||
| Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade | Q24311006 | ||
| Analysis of APAF-1 expression in human cutaneous melanoma progression | Q24315147 | ||
| Inhibition of death receptor signals by cellular FLIP | Q24316446 | ||
| A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma | Q24322614 | ||
| Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions | Q24532168 | ||
| IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases | Q24533214 | ||
| Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix | Q24537504 | ||
| FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis | Q24548247 | ||
| Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics | Q24564912 | ||
| The Bcl-2 apoptotic switch in cancer development and therapy | Q24620437 | ||
| BH3 mimetics to improve cancer therapy; mechanisms and examples | Q24655483 | ||
| Tyrosine kinase - Role and significance in Cancer. | Q24791430 | ||
| FADD adaptor in cancer | Q24795895 | ||
| Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells | Q24813658 | ||
| The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures | Q34674397 | ||
| Activation of the PI3K/Akt pathway and chemotherapeutic resistance | Q35046899 | ||
| BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak | Q35079498 | ||
| Mitochondrial control of apoptosis: an introduction | Q35120704 | ||
| Death receptor signaling in cancer therapy | Q35137781 | ||
| A decade of caspases | Q35591686 | ||
| Control of apoptosis by p53. | Q35603381 | ||
| The IKK NF-kappa B system: a treasure trove for drug development | Q35621375 | ||
| JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis | Q35635353 | ||
| Reduced levels of ATF-2 predispose mice to mammary tumors. | Q35676210 | ||
| Changes in the apoptotic and survival signaling in cancer cells and their potential therapeutic implications | Q35699094 | ||
| Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. | Q35704798 | ||
| Signaling through the epidermal growth factor receptor during the development of malignancy | Q35729447 | ||
| Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks | Q35743146 | ||
| Tyrosine kinase receptors as attractive targets of cancer therapy | Q35749774 | ||
| The proteasome: a suitable antineoplastic target | Q35762448 | ||
| Kaposi's sarcoma tumor cells preferentially express Bcl-xL. | Q35782022 | ||
| Novel approaches for targeted cancer therapy | Q35793953 | ||
| Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. | Q35833088 | ||
| Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation | Q35844144 | ||
| Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia | Q35849887 | ||
| Apoptosome dysfunction in human cancer | Q35927928 | ||
| Intrinsic tumour suppression | Q35953133 | ||
| Targeting apoptosis pathways in cancer therapy | Q35971851 | ||
| Anti-apoptotic action of API2-MALT1 fusion protein involved in t(11;18)(q21;q21) MALT lymphoma | Q36042483 | ||
| Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia | Q36047171 | ||
| Overview of cell death signaling pathways | Q36051647 | ||
| Transcription, apoptosis and p53: catch-22. | Q36056198 | ||
| Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs | Q36085634 | ||
| Carcinogenesis, cancer therapy and chemoprevention | Q36092823 | ||
| The caspase-8 modulator c-FLIP. | Q36099496 | ||
| Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach | Q36108280 | ||
| From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance | Q36203693 | ||
| Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL | Q36209190 | ||
| Overexpression of Bcl-2 and mutations in p53 and K-ras in resected human non-small cell lung cancers | Q71184934 | ||
| Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN | Q73766132 | ||
| p300/CBP-dependent and -independent transcriptional interference between NF-kappaB RelA and p53 | Q73838285 | ||
| Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice | Q73937614 | ||
| Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53 | Q74247134 | ||
| Phagocytosis of apoptotic cells by microglia in vitro | Q74307918 | ||
| Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases | Q77388207 | ||
| Sorafenib | Q80306647 | ||
| MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation | Q80312874 | ||
| Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia | Q80512195 | ||
| Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one? | Q80798226 | ||
| Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium | Q80982805 | ||
| Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors | Q83367527 | ||
| A transforming mutation in the pleckstrin homology domain of AKT1 in cancer | Q27646556 | ||
| Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic | Q27824826 | ||
| Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery | Q27860586 | ||
| TOR signaling in growth and metabolism | Q27860757 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| Surfing the p53 network | Q28032484 | ||
| Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status | Q28143274 | ||
| Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy | Q28176737 | ||
| Proliferation, cell cycle and apoptosis in cancer | Q28189476 | ||
| Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL | Q28200040 | ||
| Expression of Smac/DIABLO in ovarian carcinoma cells induces apoptosis via a caspase-9-mediated pathway | Q28204338 | ||
| The transcription factor nuclear factor-kappa B and cancer | Q28220764 | ||
| Cell death: critical control points | Q28240722 | ||
| Raf kinase as a target for anticancer therapeutics | Q28244900 | ||
| The transcriptional targets of p53 in apoptosis control | Q28248026 | ||
| Complicating the complexity of p53 | Q28250110 | ||
| The biology and clinical relevance of the PTEN tumor suppressor pathway | Q28272157 | ||
| Death receptors: signaling and modulation | Q28280897 | ||
| APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy | Q28287939 | ||
| IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs | Q28291174 | ||
| Dasatinib: a new step in molecular target therapy | Q28307556 | ||
| p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD | Q28592766 | ||
| A unified model for apical caspase activation | Q28609101 | ||
| The expanding role of mitochondria in apoptosis | Q28609686 | ||
| An inhibitor of Bcl-2 family proteins induces regression of solid tumours | Q29547595 | ||
| Live or let die: the cell's response to p53 | Q29547663 | ||
| ras oncogenes in human cancer: a review | Q29547769 | ||
| The phosphatidylinositol 3-Kinase AKT pathway in human cancer | Q29547860 | ||
| The pathophysiology of mitochondrial cell death | Q29547893 | ||
| Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining | Q29614339 | ||
| NF-kappaB in cancer: from innocent bystander to major culprit | Q29614603 | ||
| TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB | Q29614706 | ||
| Exploiting the PI3K/AKT pathway for cancer drug discovery | Q29615120 | ||
| Trastuzumab--mechanism of action and use in clinical practice | Q29615810 | ||
| Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer | Q29618155 | ||
| NF-kappaB at the crossroads of life and death | Q29619302 | ||
| Cellular stress response and apoptosis in cancer therapy. | Q34417153 | ||
| The origin of CD95-gene mutations in B-cell lymphoma | Q34584971 | ||
| On the origin, evolution, and nature of programmed cell death: a timeline of four billion years | Q34608767 | ||
| Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer | Q34610496 | ||
| Raf proteins and cancer: B-Raf is identified as a mutational target | Q34648534 | ||
| Lipid posttranslational modifications. Farnesyl transferase inhibitors | Q34651253 | ||
| Chronic myeloid leukaemia | Q34657509 | ||
| The MDM2 gene amplification database | Q34672224 | ||
| Signaling interplay in Ras superfamily function | Q36211186 | ||
| The Akt-mTOR tango and its relevance to cancer | Q36260264 | ||
| Mitochondria: pharmacological manipulation of cell death | Q36274960 | ||
| Promoting apoptosis as a strategy for cancer drug discovery | Q36292878 | ||
| Regulation of apoptosis: uncovering the binding determinants | Q36303190 | ||
| Targeting the IAP family of caspase inhibitors as an emerging therapeutic strategy. | Q36320283 | ||
| FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis | Q36334327 | ||
| mTOR signaling: implications for cancer and anticancer therapy | Q36365093 | ||
| Sorafenib | Q36407379 | ||
| Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma | Q36430277 | ||
| Carcinogenesis and apoptosis: paradigms and paradoxes | Q36445021 | ||
| Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. | Q36445910 | ||
| Human tumor mutants in the p110alpha subunit of PI3K. | Q36455143 | ||
| Mechanisms of drug inhibition of signalling molecules | Q36488752 | ||
| Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program | Q36490777 | ||
| Lonafarnib in cancer therapy. | Q36491847 | ||
| Where next for gefitinib in patients with lung cancer? | Q36496065 | ||
| Multiple roles of FOXO transcription factors in mammalian cells point to multiple roles in cancer | Q36522282 | ||
| Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy | Q36525426 | ||
| Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation | Q36561047 | ||
| Can NF-kappaB be a target for novel and efficient anti-cancer agents? | Q36594254 | ||
| Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? | Q36623657 | ||
| FOXO transcription factors: key regulators of cell fate | Q36628599 | ||
| Current insights into the regulation of programmed cell death by NF-kappaB. | Q36637900 | ||
| Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression | Q36637905 | ||
| Inhibitors of NF-kappaB signaling: 785 and counting | Q36637918 | ||
| Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. | Q36710840 | ||
| EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. | Q36745876 | ||
| Optimizing therapy of chronic myeloid leukemia | Q36767066 | ||
| Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer | Q36768544 | ||
| Classic and novel roles of p53: prospects for anticancer therapy | Q36769271 | ||
| Reactivation of mutant p53: molecular mechanisms and therapeutic potential | Q36777373 | ||
| The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib | Q36779184 | ||
| Role of Bcl-2 family members on apoptosis: what we have learned from knock-out mice | Q36814093 | ||
| EGFR-targeted therapies in colorectal cancer | Q36848809 | ||
| Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer | Q36903125 | ||
| Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis | Q36916764 | ||
| A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities | Q36924784 | ||
| The biology behind mTOR inhibition in sarcoma | Q36927347 | ||
| The inhibitor of apoptosis proteins as therapeutic targets in cancer | Q36975583 | ||
| Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer | Q37011976 | ||
| Strategies for overcoming imatinib resistance in chronic myeloid leukemia | Q37027402 | ||
| Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. | Q38433102 | ||
| Expression of bcl-2 family members in malignant pleural mesothelioma | Q38437441 | ||
| BCL-X expression in multiple myeloma: possible indicator of chemoresistance | Q38473024 | ||
| Transcriptional cross talk between NF-kappaB and p53. | Q39445554 | ||
| Posttranslational modification of Bcl-2 facilitates its proteasome-dependent degradation: molecular characterization of the involved signaling pathway. | Q39451489 | ||
| Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. | Q39457088 | ||
| Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals | Q39458674 | ||
| Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. | Q40046046 | ||
| Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death | Q40068228 | ||
| Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. | Q40073729 | ||
| ATF-2 controls transcription of Maspin and GADD45 alpha genes independently from p53 to suppress mammary tumors | Q40093558 | ||
| Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling | Q40095128 | ||
| Guggulsterone-induced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH2-terminal kinase | Q40099117 | ||
| The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway | Q40112927 | ||
| Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma | Q40124750 | ||
| Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor | Q40164535 | ||
| Mortalin sensitizes human cancer cells to MKT-077-induced senescence | Q40170011 | ||
| Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis | Q40236215 | ||
| Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. | Q40263616 | ||
| Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies | Q40349587 | ||
| Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor | Q40363687 | ||
| The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity | Q40399733 | ||
| Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo | Q40409799 | ||
| Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. | Q40469450 | ||
| Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer. | Q40480063 | ||
| Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome | Q40497165 | ||
| Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer | Q40507947 | ||
| Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer | Q40524353 | ||
| Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. | Q40528633 | ||
| X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells | Q40542636 | ||
| Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. | Q40606796 | ||
| Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo | Q40610363 | ||
| CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death | Q40616862 | ||
| Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. | Q40626751 | ||
| Selective expression of FLIP in malignant melanocytic skin lesions | Q40785268 | ||
| Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis | Q40815965 | ||
| Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling | Q40878328 | ||
| Bcl-xL functions downstream of caspase-8 to inhibit Fas- and tumor necrosis factor receptor 1-induced apoptosis of MCF7 breast carcinoma cells | Q41057711 | ||
| Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway | Q41159083 | ||
| Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells | Q41615168 | ||
| bcl-2 protein expression in melanocytic neoplasms of the skin. | Q42486565 | ||
| An informatics approach identifying markers of chemosensitivity in human cancer cell lines. | Q42496234 | ||
| Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor | Q42512929 | ||
| The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. | Q42705524 | ||
| Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis | Q43583436 | ||
| Protective role for c-Jun in the cellular response to DNA damage | Q43607743 | ||
| Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic | Q43882655 | ||
| Bcl-w is expressed in a majority of infiltrative gastric adenocarcinomas and suppresses the cancer cell death by blocking stress-activated protein kinase/c-Jun NH2-terminal kinase activation | Q44342332 | ||
| Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. | Q44419395 | ||
| Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. | Q44486888 | ||
| A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells | Q44714283 | ||
| Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens | Q44811732 | ||
| The discovery of receptor tyrosine kinases: targets for cancer therapy | Q44879898 | ||
| Particle assembly incorporating a VP22-BH3 fusion protein, facilitating intracellular delivery, regulated release, and apoptosis | Q45211719 | ||
| The psammaplysenes, specific inhibitors of FOXO1a nuclear export | Q46449319 | ||
| NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro | Q46790747 | ||
| EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib | Q46858893 | ||
| Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer | Q47580940 | ||
| In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours | Q48019464 | ||
| The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype | Q48059777 | ||
| Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis. | Q48316942 | ||
| Frequent mutation of the PIK3CA gene in ovarian and breast cancers | Q48924016 | ||
| Chromosomal translocations in human cancer. | Q52512616 | ||
| IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. | Q52545841 | ||
| c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications. | Q52579698 | ||
| Ribotoxic stress sensitizes glioblastoma cells to death receptor induced apoptosis: requirements for c-Jun NH2-terminal kinase and Bim. | Q53534498 | ||
| An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells. | Q53922832 | ||
| Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. | Q53948357 | ||
| Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. | Q54033436 | ||
| Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. | Q54039075 | ||
| Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression. | Q54042207 | ||
| Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. | Q54148912 | ||
| Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. | Q55043614 | ||
| Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma. | Q55473882 | ||
| Antiapoptotic Bcl-2 family protein expression increases with progression of oligodendroglioma. | Q55476546 | ||
| The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak | Q57279398 | ||
| Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers | Q57694014 | ||
| Cell suicide for beginners | Q59090007 | ||
| Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148 | Q59831038 | ||
| A matter of life and death | Q63408384 | ||
| INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201 | Q64377139 | ||
| Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB | Q64381570 | ||
| Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. | Q64930197 | ||
| Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
| FOXO transcription factors at the interface between longevity and tumor suppression | Q29620472 | ||
| IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools | Q30429006 | ||
| Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines | Q30967010 | ||
| Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity | Q31038912 | ||
| Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. | Q31041084 | ||
| Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5. | Q31120918 | ||
| Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias | Q31379722 | ||
| Hypoxia death stimulus induces translocation of p53 protein to mitochondria. Detection by immunofluorescence on whole cells | Q31864081 | ||
| Inactivation of the apoptosis effector Apaf-1 in malignant melanoma | Q31984891 | ||
| Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells | Q33181379 | ||
| Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. | Q33209208 | ||
| TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility | Q33239894 | ||
| Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts | Q33295289 | ||
| A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. | Q33346173 | ||
| U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval | Q33364668 | ||
| The role of p53 in tumour suppression: lessons from mouse models | Q33538155 | ||
| Caspase structure, proteolytic substrates, and function during apoptotic cell death | Q33782479 | ||
| Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib | Q33821320 | ||
| Caspases - controlling intracellular signals by protease zymogen activation | Q33857511 | ||
| AKT plays a central role in tumorigenesis | Q33944165 | ||
| The p53 tumor suppressor gene: from molecular biology to clinical investigation. | Q33981374 | ||
| Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice | Q33982420 | ||
| Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase | Q34016286 | ||
| Defining CD95 as a tumor suppressor gene | Q34042835 | ||
| The molecular biology of chronic myeloid leukemia. | Q34079452 | ||
| Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. | Q34131747 | ||
| Death receptor signals to mitochondria | Q34139596 | ||
| Specific targeted therapy of chronic myelogenous leukemia with imatinib | Q34215244 | ||
| Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. | Q34250223 | ||
| Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase | Q34323951 | ||
| AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity | Q34333732 | ||
| Signal transduction by tumor necrosis factor and its relatives | Q34341941 | ||
| A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death | Q34346499 | ||
| P433 | issue | 4 | |
| P921 | main subject | apoptotic process | Q14599311 |
| P304 | page(s) | 1124-1149 | |
| P577 | publication date | 2008-07-01 | |
| P1433 | published in | Journal of Cellular Biochemistry | Q6294917 |
| P1476 | title | Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities | |
| P478 | volume | 104 |
| Q92069847 | AMPK activation can delay aging |
| Q38877050 | Acetogenins from Annona muricata as potential inhibitors of antiapoptotic proteins: a molecular modeling study |
| Q92127928 | Ailanthone Induces Cell Cycle Arrest and Apoptosis in Melanoma B16 and A375 Cells |
| Q42068051 | Apogossypolone (ApoG2) induces ROS-dependent apoptosis and reduces invasiveness of PC12 cells in vitro and in vivo |
| Q38228349 | Apoptosis and molecular targeting therapy in cancer |
| Q26750639 | Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies |
| Q36589966 | Apoptosis is induced in cancer cells via the mitochondrial pathway by the novel xylocydine-derived compound JRS-15. |
| Q64054432 | Apoptosis regulation in adrenocortical carcinoma |
| Q35088734 | Apoptotic cell signaling in cancer progression and therapy |
| Q90647107 | Asteriscus graveolens Extract in Combination with Cisplatin/Etoposide/Doxorubicin Suppresses Lymphoma Cell Growth through Induction of Caspase-3 Dependent Apoptosis |
| Q51013700 | BCL2 protein signalling determines acute responses to neoadjuvant chemoradiotherapy in rectal cancer. |
| Q30397015 | Cancer Therapy Due to Apoptosis: Galectin-9. |
| Q34143322 | Cell death or survival: The double-edged sword of environmental and occupational toxicity. |
| Q92129182 | Clinical and in vitro Study of Novel Long Non-Coding RNA lncUSMycN in Breast Cancer |
| Q35025461 | Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells. |
| Q41839933 | Comprehensive review on betulin as a potent anticancer agent. |
| Q46176412 | Construction of some cytotoxic agents with aurone and furoaurone scaffolds |
| Q92069595 | Critical physiological and pathological functions of Forkhead Box O tumor suppressors |
| Q37287006 | Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody. |
| Q47143415 | Dual Site Phosphorylation of Caspase-7 by PAK2 Blocks Apoptotic Activity by Two Distinct Mechanisms |
| Q92582444 | Effects of gossypol on apoptosis‑related gene expression in racially distinct triple‑negative breast cancer cells |
| Q47732063 | Facile synthesis of simple 2-oxindole-based compounds with promising antiproliferative activity |
| Q93357394 | Functional role of RBM10 in lung adenocarcinoma proliferation |
| Q97073531 | Glycolysis is suppressed by DCZ0801-induced inactivation of the Akt/mTOR pathway in Multiple Myeloma |
| Q35853333 | Gonadotropin-mediated chemoresistance: Delineation of molecular pathways and targets |
| Q90330408 | HAART induces cell death in a cervical cancer cell line, HCS-2: A Scanning Electron Microscopy study |
| Q35782071 | High levels of X-linked Inhibitor-of-Apoptosis Protein (XIAP) are indicative of radio chemotherapy resistance in rectal cancer. |
| Q37836489 | How to improve the immunogenicity of chemotherapy and radiotherapy |
| Q37446629 | Identification of GAS1 as an epirubicin resistance-related gene in human gastric cancer cells with a partially randomized small interfering RNA library |
| Q43084011 | In vitro anticancer effect of venom from Cuban scorpion Rhopalurus junceus against a panel of human cancer cell lines |
| Q90154703 | Induction of apoptosis through extrinsic/intrinsic pathways and suppression of ERK/NF-κB signalling participate in anti-glioblastoma of imipramine |
| Q49590876 | Knockdown of microRNA-29a regulates the expression of apoptosis-related genes in MCF-7 breast carcinoma cells |
| Q64116877 | Long Non-Coding RNA and Breast Cancer |
| Q33761744 | Mitochondrial VDAC1-based peptides: Attacking oncogenic properties in glioblastoma. |
| Q51064155 | Modulatory efficacy of dieckol on xenobiotic-metabolizing enzymes, cell proliferation, apoptosis, invasion and angiogenesis during NDEA-induced rat hepatocarcinogenesis. |
| Q53069153 | Molecular alterations associated with chronic exposure to cigarette smoke and chewing tobacco in normal oral keratinocytes. |
| Q59130161 | N-Substituted Pyrido-1,4-Oxazin-3-Ones Induce Apoptosis of Hepatocellular Carcinoma Cells by Targeting NF-κB Signaling Pathway |
| Q89926626 | Network modeling of patients' biomolecular profiles for clinical phenotype/outcome prediction |
| Q36247293 | Nimbolide Induces ROS-Regulated Apoptosis and Inhibits Cell Migration in Osteosarcoma |
| Q38840886 | Nuclear translocation of nuclear factor kappa B is regulated by G protein signaling pathway in arsenite-induced apoptosis in HBE cell line. |
| Q38329332 | Phosphorylation of the transcription factor YY1 by CK2α prevents cleavage by caspase 7 during apoptosis |
| Q39114961 | Poor antibody validation is a challenge in biomedical research: a case study for detection of c-FLIP. |
| Q92443197 | Protein Kinase B Inactivation Is Associated with Magnolol-Enhanced Therapeutic Efficacy of Sorafenib in Hepatocellular Carcinoma In Vitro and In Vivo |
| Q92063390 | Pseudolaric acid B inhibits PAX2 expression through Wnt signaling and induces BAX expression, therefore promoting apoptosis in HeLa cervical cancer cells |
| Q39096529 | Quercetin increases the efficacy of glioblastoma treatment compared to standard chemoradiotherapy by the suppression of PI-3-kinase-Akt pathway |
| Q61818422 | Redoxins as gatekeepers of the transcriptional oxidative stress response |
| Q37301910 | The La protein counteracts cisplatin-induced cell death by stimulating protein synthesis of anti-apoptotic factor Bcl2. |
| Q39723123 | The anti-apoptotic protein lifeguard is expressed in breast cancer cells and tissues. |
| Q38799319 | The effect of nicotine on the expressions of the α7 nicotinic receptor gene and Bax and Bcl-2 proteins in the mammary gland epithelial-7 breast cancer cell line and its relationship to drug resistance |
| Q99575995 | The interaction mechanism between autophagy and apoptosis in colon cancer |
| Q39709305 | The neem limonoids azadirachtin and nimbolide induce cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells |
| Q37357932 | The story of human cytomegalovirus and cancer: increasing evidence and open questions |
| Q41869097 | Thromboxane A2 modulates cisplatin-induced apoptosis through a Siva1-dependent mechanism. |
| Q93015446 | Tri-arginine exosite patch of caspase-6 recruits substrates for hydrolysis |
Search more.